Seaport Therapeutics, Inc. 8K

Seaport Therapeutics reported Q2 2026 results, detailing strong post-IPO liquidity, expanded losses driven by IPO-related stock compensation, and significant clinical and corporate progress across its neuropsychiatric pipeline.

On August 3, 2026, Seaport Therapeutics, Inc. reported its second quarter 2026 financial results and provided a business update highlighting advancement of its neuropsychiatric pipeline, including ongoing enrollment in the potentially registration-enabling Phase 2b BUOY-1 trial of lead candidate GlyphAllo in major depressive disorder, progress of a Phase 1 driving simulation study of GlyphAllo, positive Phase 1 proof-of-concept data for GlyphAgo supporting initiation of Phase 2a and Phase 2b trials in generalized anxiety disorder, continued preclinical development of non-hallucinogenic neuroplastogen Glyph2BLSD, completion of an upsized IPO in May 2026 raising $260.0 million in gross proceeds and extending cash runway into 2029, appointment of industry veteran Sharon Mates, Ph.D. to the board, and a higher quarterly net loss driven largely by one-time, non-cash stock-based compensation related to the IPO.

Filing Facts

CIK

2042347

Ticker

SPTX

Form

8K

Source Type

fda

Accession

0001193125-26-329528

Alert Tier

6